Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
April 2006
Features
Pharmaceutical Approval Update: Oncology
Dr. Goldenberg reviews cetuximab (Erbitux) combined with radiation therapy for cancer of the head and neck; sunitinib (Sutent) for gastrointestinal stromal tumors (GISTs) and advanced kidney cancer; and sorafenib tosylate (Nexavar)
for advanced renal cell carcinoma.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
22nd Annual Meeting of the American Academy of Pain Medicine
The authors report on advances with morphine sulfate and oxymorphone for back pain, ziconotide for chronic pain, intranasal morphine and transdermal hydromorphone for postoperative pain, fentanyl tablets for cancer-related breakthrough pain, lower-dose epidural steroids for lumbar radiculopathy and spinal stenosis, and duloxetine for diabetic peripheral neuropathic pain.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Letter to the Editor
Drugs for Less: Still More Press
Continuing Education Credit
Principles of Epidemiology for Clinical and Formulary Management Professionals
The authors discuss the fundamentals of epidemiology in the context of cohort studies, case-control studies, and experimental studies (clinical trials) and describe the importance of epidemiology in making formulary decisions.
David D. Dore, PharmD, PhD Candidate, E. Paul Larrat, MBA, PhD, and F. Randy Vogenberg, RPh, PhD
Departments
Editorial
Toot Your Horn
David Nash, MD, MBA, discusses the improvements being made in the quality of drug delivery by the Medication Quality Subcommittee at Thomas Jefferson University Hospital.
David Nash, MD, MBA
Medication Errors
Pain Scales Don’t Weigh Every Risk
Matthew Grissinger, RPh, FASCP, explains how noble efforts to manage pain in hospitals can inadvertently compromise patient safety.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
New FDA Commissioner to Face Vital Drug Safety Concerns: Companies Slow to Complete Postmarketing Trials
Stephen Barlas emphasizes the need for drug manufacturers to complete promised postmarketing (phase 4) trials in a timely way—this is just one of many challenges facing the new FDA Commissioner.
Stephen Barlas
Drug News
New Drugs/Drug News/New Medical Devices
P&T presents the latest studies and information
about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Rituximab for Patients with Refractory Rheumatoid Arthritis
The authors review rituximab (Rituxan) for patients with refractory rheumatoid arthritis.
Patty Ghazvini, PharmD, Angela Singh, PharmD, Phillip Treadwell, PharmD, Marlon Honeywell, PharmD, and Natosha Canty, MD
